mIWG-MRT-ECNM responses over time: pooled results from the phase 1 EXPLORER and interim phase 2 PATHFINDER studies. Swimmer plots demonstrate deepening mIWG-MRT-ECNM responses over time in 53 overall response-evaluable patients from the pooled population of patients treated with avapritinib at a dose of ≤200 mg daily. CI, clinical improvement; DOR, duration of response; mIWG-MRT-ENM, modified International Working Group-Myeloproliferative Neoplasms Research and Treatment European Competence Network on Mastocytosis; NE, not evaluable; PD, progressive disease; SD, stable disease; TTR, time to response.